Emergent BioSolutions Q2 FY26 net loss widens to $180.2 million; revenue rises 66% to $234.3 million
Reuters2026/08/05 20:53- Emergent BioSolutions posted Q2 revenue of $234.3 million, up 66% year over year; GAAP net loss widened to $180.2 million on a $191.3 million non-cash impairment.
- GAAP gross margin rose 14 percentage points to 50%; non-GAAP adjusted EBITDA climbed to $96.5 million, lifting margin to 41% from 23%.
- Naloxone revenue fell 22% to $52.4 million, while smallpox MCM revenue more than doubled to $101.6 million; other products revenue rose to $54.1 million.
- Launched an organizational restructuring expected to deliver about $40 million in annualized savings, including a reduction of about 90 roles and a new Growth organization.
- Cut full-year revenue outlook to $645 million-$675 million from $720 million-$760 million; projected GAAP net loss of $245 million-$225 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan optimistic forecast: Strengthening yen may ease pressure on Japanese bonds, Japanese AI and semiconductor sectors expected to recover ahead of schedule
JPMorgan believes that a stronger yen is likely to ease the upward pressure on Japanese government bond yields, thereby boosting an early recovery for AI and semiconductor stocks listed in Tokyo.
Hunter Biden Lays Out LAPTOP Airdrop Plan Before Base Debut
Nihon Dempa Kogyo Expected to Benefit From Growing Data-Center Demand -- Market Talk
The $35 billion acquisition of Teck Resources initiates a revaluation of valuations; Anglo American (AAUKF.US) receives an "Outperform" rating from Scotiabank.
Scotiabank has covered Anglo American (AAUKF.US) for the first time, assigning it an “Outperform” rating with a target price of £52 per share.
Crypto prices
More
